Active Filter(s):
Details:
Through the divestment, Esteve expand its rare disease business portfolio, by including Metopirone (metyrapone), can be used to treat the signs and symptoms of Cushing's syndrome by lowering high levels of cortisol a hormone produced by the adrenal glands.
Lead Product(s): Metyrapone
Therapeutic Area: Endocrinology Product Name: Metopirone
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Esteve Healthcare
Deal Size: $294.2 million Upfront Cash: $203.3 million
Deal Type: Divestment April 25, 2024
Details:
The randomized, double-blind, placebo-controlled Phase 2 clinical trial is supported by funding from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health and will evaluate EMB-001 as a treatment option for patients with cocaine use disorder.
Lead Product(s): Metyrapone,Oxazepam
Therapeutic Area: Psychiatry/Psychology Product Name: EMB-001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020